
Rachel Riechelmann
@rachelriechelm2
Clin Oncology Director-AC Camargo Cancer Canter 🇧🇷focus: neuroendocrine tumors, colorectal/anal cancer. Love animals, travels, research. All are born equal.
ID: 1147280863039819777
05-07-2019 23:07:27
1,1K Tweet
1,1K Followers
152 Following

I am very honored to be nominated for Director of Membership of ESMO - Eur. Oncology Election. 😊 the President’s call: #ESMOMembers vote for leaders who’ll shape ESMO’s future. Vote for Directors of Education, Public Policy & Membership , and Chair and members of the Nomination Committee






Most viewed this week from JAMA Oncology: Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/45zBluy



#ASCO25 last but not least Rodrigo Dienstmann_MD_MBA Frederick Chite MD FASCO we talk about Scalable and Sustainable Innovation in Global Oncology in LMIC & HIC. Global economic cost of cancer will reach USD$25.2 trillions between 20220-25 Instituto Nacional de Cancerología education is key!!


On #WorldEnvironmentDay, ESMO stands w/ the global community to #BeatPlasticPollution. #Microplastics are found in organs and tumours. More research needed to understand their role in cancer development Pawel Sobczuk 🔗 ow.ly/Q8xT50W3VCP #ESMODailyReporter




JCO Global Oncology LATAM-Women face challenges in family planning, with longer work hours negatively affecting the likelihood of having children, especially among attending physicians & residents Instituto Nacional de Cancerología Julia Ismael Regina Barragan-Carrillo ASCO



Thank you to all colleagues who voted in the 2025 #ESMO election I'm honored to announce that I was elected as Director of Membership 😊 my aim is to extend ESMO - Eur. Oncology benefits to much more members across the globe!

Proud of our Vanderbilt University Medical Center heme/onc fellow Margaret Wheless, MD for her first author publication on FGFR-altered mCRC. A true team effort across institutions, supported by ACCRU and Incyte Tanios Bekaii-Saab, MD Dr. Cathy Eng Dr. jordan berlin

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors JAMA Oncology doi.org/10.1001/jamaon… 🔎128 studies, 343 SOTRs 👉Acute rejection: 36.2%; graft loss: 18%, lower risk w/ steroids & mTOR 👉ORR: 31% 🧐ICI my be considered in


Poorly Differentiated Neuroendocrine Carcinomas - by Garcia-Carbonero's Lab at ESMO - Eur. Oncology #ESMOGI25 👉Poorly dif 👉High Ki67 👉Agressive 🏥Chemo ASAP (PlatinumEtoposide) ✅FDG-PET (⛔️SSTR; 28% would to a Ga-PET 😫) 🤞🏻IO promising #ESMOAmbassadors Rachel Riechelmann Juan OConnor


Small @myesmo #ESMOGI25 reunion in the faculty room! Great way to start the AM. Some of my fave people: Dr. Eileen O’Reilly, Angela Lamarca and Karyn Goodman, MD, MS ☹️Missed our photo 📸opportunity with Rachel Riechelmann! #ESMOAmbassadors #cancer #CancerResearch


Wonderful faculty dinner last night! 🙏🏻 ESMO - Eur. Oncology Karyn Goodman, MD, MS Erika Ruiz-Garcia Prof. Irit Ben-Aharon Rachel Riechelmann Lizzy Smyth Teresa Macarulla Juan OConnor and so many others! #ESMOGI25 #ESMOAmbassadors #cancer #CancerResearch


#ESMOGI25 #neuroendocrinetumors session with Juan OConnor Garcia-Carbonero's Lab Sara De Dosso ESMO - Eur. Oncology
